KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Overall, a decrease of the percentage of GFP+ c-Kit+ cells (P = 0.0095, Fig. 1m) and an increase of GFP+ CD34+ (P = 0.0003, Fig. S2A) and GFP+ CD13+ (P = 0.0019, Fig. S2B) cells were observed in mice with BCR-ABL1T315I+ CML.